SCHEMBL4606133

SCHEMBL4606133

CCC(=O)Nc1ccc(Oc2ccccc2N2CCN(C)CC2)cc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
RECQL P46063 1/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
HTR1A P08908 2/20 0.43
HTR7 P34969 2/20 0.43
POLB P06746 1/20 0.43
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606300 0.91 NPC1 (0.51) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL4605187 0.89 L3MBTL1 (0.52) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL4604092 0.85 ALDH1A1 (0.49) MEN1KMT2AGAAMAPK1HSD17B10
SCHEMBL4605960 0.85 GAA (0.47) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL4603669 0.81 ALDH1A1 (0.53) MEN1KMT2AGAAHSD17B10ALDH1A1
SCHEMBL4604249 0.81 POLB (0.54) GAAHSD17B10ALDH1A1KDM4EPKM
SCHEMBL4606032 0.78 ALDH1A1 (0.46) MEN1KMT2AGAAALDH1A1SMN1; SMN2
SCHEMBL4604342 0.78 KDM4E (0.49) GAAHSD17B10ALDH1A1KDM4EPKM
SCHEMBL4605135 0.78 KDM4E (0.49) GAAMAPTMAPK1HSD17B10ALDH1A1
SCHEMBL4603286 0.77 ALDH1A1 (0.43) MEN1KMT2AGAAMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 MEN1 313/4885KMT2A 3945/4885RECQL 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.